Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Pfizer Inc (PFE) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines as of [[ item.timeDateDisplayLong ]]
Asian shares meander as ECB-inspired rally fades

KUALA LUMPUR, Malaysia (AP) — Asian shares meandered Friday as an overnight rally in U.S. markets helped by the European Central Bank's decision to extend its bond-buying economic stimulus program faded....

Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK

Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.

Should Biotech Investors Worry About Donald Trump?

It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.

Asian stocks advance ahead of ECB decision

SEOUL, South Korea (AP) — Asian shares rose on Thursday after an overnight surge on U.S. markets. Investors were focused the European Central Bank's meeting later in the day.

Business Highlights


Prologis and Western Digital climb; Pfizer skids

NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday:

Markets Right Now: Dow, S&P 500 surge to record high closes

NEW YORK (AP) — The latest on developments in financial markets (All times local):

Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.

Pfizer fined for hiking epilepsy drug price 2,600 pct in UK

LONDON (AP) — British regulators fined U.S. drugmaker Pfizer and distributor Flynn Pharma a record 89.4 million pounds ($112.7 million) Wednesday for increasing the cost of an epilepsy drug by as much...

Pfizer Leukemia Drug Meets Primary Endpoint in Phase III

Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and CEO, at the Guggenheim 4th Annual Boston Healthcare Conference on ...

Can't buy love? Drug price hikes put sex beyond reach

TRENTON, N.J. (AP) — Imagine not being able to afford one of life's great pleasures — sex.

Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Today, Pfizer Inc. and its partner Avillion LLP announced results from the Phase 3 BFORE (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment) trial demonstrating...

Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia...

New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Today, Pfizer Inc. (NYSE:PFE) announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose...

Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days

Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from...

Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

5 Top Performing S&P 500 Stocks of November

President-elect Donald Trump has proposed a raft of fiscal-stimulus measures, which has pushed the S&P 500 to almost an all-time high in November

Van Meerten Stock Picks

5 NAsdaq 100 Stocks for Momentum Investors
Today I wanted to find the 5 NASDAQ 100 Index stocks that had the most consistent momentum so I used Barchart to sort the NASDAQ 100 Index stocks first by the most frequent number of new highs in the last month.
PCAR +0.44 , TMUS +0.16 , AMAT +0.20 , SBUX -0.11 , AAL -0.60
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ16 +0.10%) are up +0.02% and European stocks are up +0.30% at an 11-month high as the markets expect the ECB later today to announce an extension of its QE program. Government bond prices fell... Read More

Chart of the Day

KMG Chemicals (KMG) is the Barchart Chart of the Day.  The specialty chemical company has a Trend Spotter buy signal, a Weighted Alpha of 56.07+ and gained 81.25% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed 2 to 4 ½ cents lower today as traders took money off the table ahead of Friday’s USDA reports. The weekly USDA Export Sales report showed sales for the week ending 12/1 were up 96% vs. Thanksgiving week and up 45% v...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.